Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs

 

Quality Medicines Use Data Can Lead to Better Health Systems, and Better Outcomes

In this blog, we provide a rapid overview of the sources and wider uses of medicines data to strengthen health systems in LMIC settings, with a focus on Ghana. We argue that having credible and comprehensive data on medicines use leads to better decision making and better medicines policy. These are necessary—although not sufficient—pre-conditions to improve health outcomes in a financially sustainable way. 

An image of a doctor working on a laptop.

Rapid Priority Setting in Low- and Middle-Income Countries: The Potential of Adaptive Health Technology Assessments

Health budgets are limited and decision makers in all countries face very challenging decisions about which health interventions will be provided, and which will not. COVID has only added to this pressing priority setting problem. In this blog, we highlight key takeaways from our recent commentary in the BMJ Global Health, where we make the case for “adaptive health technology assessment,” or “aHTA.”

A figure of the summary of costs and consequences to consider in COVID-19 vaccine HTA.

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis

In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.